nach oben

Current Colorectal Cancer Reports

Erschienen in:

29.10.2018 | Systemic Therapies in Colorectal Cancer (RD Kim, Section Editor)

The Role of HER2 Testing in Advanced Colorectal Cancer

verfasst von: Rutika Mehta

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

About 1/3 of all metastatic colorectal cancer (mCRC) patients may harbor a mutation in the KRAS or NRAS gene suggesting inefficacy of EGFR inhibitors cetuximab and panitumumab. In spite of tailoring treatment in RAS wild-type patients to receive EGFR inhibitors, not all show response.

Recent Findings

Studies have shown that HER2-neu amplification/alteration in addition to alteration in BRAF and PI3KA may explain resistance to EGFR inhibitors. Several pre-clinical studies have identified that HER2-neu amplification can result in both de novo and acquired resistance to EGFR inhibitors. Recently, several clinical studies have highlighted the use of single or combination HER2-neu directed therapies in HER2-neu amplified/overexpressed mCRC.

Summary

About 5% mCRC patients will demonstrate HER2-neu overexpression and response to HER2-neu-directed therapies can be in the range of 30–38%. Patients not responding to EGFR-inhibitors warrant testing for HER2-neu testing to explain resistance. In the near future, HER2-neu testing is likely to be integrated into our routine clinical practice for management of metastatic colorectal cancer patients.

Siegel RL, Miller KD, Jemal A. Cancer statistics. CA Cancer J Clin. 2018;68(1):7–30. https://doi.org/10.3322/caac.21442.

Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–20. https://doi.org/10.1056/NEJMoa1500596.CrossRefPubMedPubMedCentral

Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371(17):1609–18. https://doi.org/10.1056/NEJMoa1403108.CrossRefPubMed

Loupakis F, Cremolini C, Salvatore L, Masi G, Sensi E, Schirripa M, et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer. 2014;50(1):57–63. https://doi.org/10.1016/j.ejca.2013.08.024.CrossRefPubMed

Zarkavelis G, Boussios S, Papadaki A, Katsanos KH, Christodoulou DK, Pentheroudakis G. Current and future biomarkers in colorectal cancer. Ann Gastroenterol. 2017;30(6):613–21. https://doi.org/10.20524/aog.2017.0191.CrossRefPubMedPubMedCentral

Chmielecki J, Ross JS, Wang K, Frampton GM, Palmer GA, Ali SM, et al. Oncogenic alterations in ERBB2/HER2 represent potential therapeutic targets across tumors from diverse anatomic sites of origin. Oncologist. 2015;20(1):7–12. https://doi.org/10.1634/theoncologist.2014-0234.CrossRefPubMed

Ross JS, Fakih M, Ali SM, Elvin JA, Schrock AB, Suh J, et al. Targeting HER2 in colorectal cancer: the landscape of amplification and short variant mutations in ERBB2 and ERBB3. Cancer. 2018;124(7):1358–73. https://doi.org/10.1002/cncr.31125.CrossRefPubMed

Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X.CrossRefPubMed

Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320–68. https://doi.org/10.1634/theoncologist.2008-0230.CrossRefPubMed

10.

Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014;25(3):282–303. https://doi.org/10.1016/j.ccr.2014.02.025.CrossRefPubMedPubMedCentral

11.

Herter-Sprie GS, Greulich H, Wong KK. Activating mutations in ERBB2 and their impact on diagnostics and treatment. Front Oncol. 2013;3:86. https://doi.org/10.3389/fonc.2013.00086.CrossRefPubMedPubMedCentral

12.

Jasra S, Opyrchal M, Norton L, Mehta R. A rare case of S310F somatic ERBB2 mutation in a HER2-nonamplified breast Cancer. Clin Breast Cancer. 2017;17(1):e37–41. https://doi.org/10.1016/j.clbc.2016.08.001.CrossRefPubMed

13.

•• Valtorta E, Martino C, Sartore-Bianchi A, Penaullt-Llorca F, Viale G, Risio M, et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol. 2015;28(11):1481–91. https://doi.org/10.1038/modpathol.2015.98. This is the study which establishes guidelines for HER2-neu testing in colorectal cancer. CrossRefPubMed

14.

•• Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, SJ MC, Penault-Llorca F, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29(5):1108–19. https://doi.org/10.1093/annonc/mdy100. This is an excellent review article that describes role of HER2-neu in colorectal cancer. CrossRefPubMedPubMedCentral

15.

Laurent-Puig P, Balogoun R, Cayre A, Malicot KL, Tabernero J, Mini E, et al. ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8). Ann Oncol. 2016;27 (suppl_abstr 459O).

16.

Richman SD, Southward K, Chambers P, Cross D, Barrett J, Hemmings G, et al. HER2 overexpression and amplification as a potential therapeutic target in colorectal cancer: analysis of 3256 patients enrolled in the QUASAR, FOCUS and PICCOLO colorectal cancer trials. J Pathol. 2016;238(4):562–70. https://doi.org/10.1002/path.4679.CrossRefPubMedPubMedCentral

17.

Missiaglia E, Jacobs B, D'Ario G, Di Narzo AF, Soneson C, Budinska E, et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol. 2014;25(10):1995–2001. https://doi.org/10.1093/annonc/mdu275.CrossRefPubMed

18.

Ingold Heppner B, Behrens HM, Balschun K, Haag J, Kruger S, Becker T, et al. HER2/neu testing in primary colorectal carcinoma. Br J Cancer. 2014;111(10):1977–84. https://doi.org/10.1038/bjc.2014.483.CrossRefPubMedPubMedCentral

19.

• Salem ME, Weinberg BA, Xiu J, El-Deiry WS, Hwang JJ, Gatalica Z, et al. Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers. Oncotarget. 2017;8(49):86356–68. https://doi.org/10.18632/oncotarget.21169. This study describes the relative frequencies of different genetic alterations in colorectal cancer based on location of tumor. CrossRefPubMedPubMedCentral

20.

Kavuri SM, Jain N, Galimi F, Cottino F, Leto SM, Migliardi G, et al. HER2 activating mutations are targets for colorectal cancer treatment. Cancer Discov. 2015;5(8):832–41. https://doi.org/10.1158/2159-8290.CD-14-1211.CrossRefPubMedPubMedCentral

21.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189–94. https://doi.org/10.1038/nature25475.CrossRefPubMedPubMedCentral

22.

Kloth M, Ruesseler V, Engel C, Koenig K, Peifer M, Mariotti E, et al. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in lynch and lynch-like colorectal cancer. Gut. 2016;65(8):1296–305. https://doi.org/10.1136/gutjnl-2014-309026.CrossRefPubMed

23.

Miyamoto Y, Suyama K, Baba H. Recent advances in targeting the EGFR signaling pathway for the treatment of metastatic colorectal cancer. Int J Mol Sci. 2017;18(4). https://doi.org/10.3390/ijms18040752.

24.

Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: from heterogeneity to convergent evolution. Cancer Discov. 2014;4(11):1269–80. https://doi.org/10.1158/2159-8290.CD-14-0462.CrossRefPubMed

25.

Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov. 2011;1(6):508–23. https://doi.org/10.1158/2159-8290.CD-11-0109.CrossRefPubMed

26.

• Yonesaka K, Zejnullahu K, Okamoto I, Satoh T, Cappuzzo F, Souglakos J, et al. Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med. 2011;3(99):99ra86. https://doi.org/10.1126/scitranslmed.3002442. This is an excellent study that studies the mechanisms of resistance to EGFR inhibitors. CrossRefPubMedPubMedCentral

27.

Martin V, Landi L, Molinari F, Fountzilas G, Geva R, Riva A, et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br J Cancer. 2013;108(3):668–75. https://doi.org/10.1038/bjc.2013.4.CrossRefPubMedPubMedCentral

28.

Raghav KPS, Overman MJ, Yu R, Meric-Bernstam F, Menter D, Kee BK, et al. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J Clin Oncol. 2016;34(15_suppl):3517. https://doi.org/10.1200/JCO.2016.34.15_suppl.3517.CrossRef

29.

Leto SM, Sassi F, Catalano I, Torri V, Migliardi G, Zanella ER, et al. Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin Cancer Res. 2015;21(24):5519–31. https://doi.org/10.1158/1078-0432.CCR-14-3066.CrossRefPubMed

30.

Lee WS, Park YH, Lee JN, Baek JH, Lee TH, Ha SY. Comparison of HER2 expression between primary colorectal cancer and their corresponding metastases. Cancer Med. 2014;3(3):674–80. https://doi.org/10.1002/cam4.228.CrossRefPubMedPubMedCentral

31.

Parikh A, Atreya C, Korn WM, Venook AP. Prolonged response to HER2-directed therapy in a patient with HER2-amplified, rapidly progressive metastatic colorectal cancer. J Natl Compr Cancer Netw. 2017;15(1):3–8.CrossRef

32.

Ramanathan RK, Hwang JJ, Zamboni WC, Sinicrope FA, Safran H, Wong MK, et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Investig. 2004;22(6):858–65.CrossRef

33.

Mohammed TA, Dennie T, Holen KD. Activity of oxaliplatin plus capecitabine (CapeOx) with lapatinib for metastatic colorectal cancer: results from two patients treated on a clinical study. Clin Adv Hematol Oncol. 2011;9(6):492–500.PubMed

34.

Martinelli E, Troiani T, Sforza V, Martini G, Cardone C, Vitiello PP, et al. Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. ESMO Open. 2018;3(1):e000299. https://doi.org/10.1136/esmoopen-2017-000299.CrossRefPubMedPubMedCentral

35.

• Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, Bergamo F, et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016;17(6):738–46. https://doi.org/10.1016/S1470-2045(16)00150-9. This is a landmark trial of HER2-neu-targeted agents in HER2-neu expressing colorectal cancers. CrossRefPubMed

36.

Siena S, Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, et al. Abstract CT005: final results of the HERACLES trial in HER2-amplified colorectal cancer. Cancer Res. 2017;77(13 Supplement):CT005-CT. https://doi.org/10.1158/1538-7445.am2017-ct005.CrossRef

37.

Siena S, Bardelli A, Sartore-Bianchi A, Martino C, Siravegna G, Magri’ A, et al. HER2 amplification as a ‘molecular bait’ for trastuzumab-emtansine (T-DM1) precision chemotherapy to overcome anti-HER2 resistance in HER2 positive metastatic colorectal cancer: the HERACLES-RESCUE trial. J Clin Oncol. 2016;34(4_suppl):TPS774-TPS. https://doi.org/10.1200/jco.2016.34.4_suppl.tps774.CrossRef

38.

• Hainsworth JD, Meric-Bernstam F, Swanton C, Hurwitz H, Spigel DR, Sweeney C, et al. Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open-label, phase iia multiple basket study. J Clin Oncol. 2018;36(6):536–42. https://doi.org/10.1200/jco.2017.75.3780. This is an improtant trial which included HER2-neu expressing colorectal cancer patients that were treated with HER2-neu-targeted agents and achieved good response rates. CrossRefPubMed

39.

Li BT, Makker V, Buonocore DJ, Offin MD, Olah ZT, Panora E, et al. A multi-histology basket trial of ado-trastuzumab emtansine in patients with HER2 amplified cancers. J Clin Oncol. 2018;36(suppl_abstr 2502).

40.

Iwata H, Tamura K, Doi T, Tsurutani J, Modi S, Park H, et al. Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: long-term results of a large phase 1 study with multiple expansion cohorts. J Clin Oncol. 2018;36(suppl; abstr 2501).

41.

Meric-Bernstam F, Beeram M, Mayordomo JI, Hanna DL, Ajani JA, Murphy AAB, et al. Single agent activity of ZW25, a HER2-targeted bispecific antibody, in heavily pretreated HER2-expressing cancers. J Clin Oncol. 2018;36(suppl_abstr 2500).

Titel: The Role of HER2 Testing in Advanced Colorectal Cancer
verfasst von: Rutika Mehta
Publikationsdatum: 29.10.2018
Verlag: Springer US
Erschienen in: Current Colorectal Cancer Reports / Ausgabe 6/2018
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI: https://doi.org/10.1007/s11888-018-0417-6

Springer Medizin

The Role of HER2 Testing in Advanced Colorectal Cancer

Abstract

Purpose of Review

Recent Findings

Summary

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2018

Insights Into the Relationship Between Gut Microbiota and Colorectal Cancer

Overview of Microsatellite Instability and Immune Checkpoint Inhibitors in Colorectal Cancer

Microbiome and Colorectal Cancer

The Role of Energy Balance on Colorectal Cancer Survival

What Is the Best Systemic Therapy for Left-sided RAS Wild-type Metastatic Colorectal Cancer?

Total Neoadjuvant Therapy (TNT) in Rectal Cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie